Phase III mi­graine flop sends a small-cap biotech play­er in­to a dead­ly tail­spin

Last week
R&D

Trel­e­gy gets FDA thumbs-up for asth­ma, be­com­ing first triple-com­bo ther­a­py in the US

Last week
Regulatory

FDA knocks back Sarep­ta in Duchenne gene ther­a­py race with Pfiz­er, but an­a­lysts urge cau­tion

Last week
R&D
Regulatory

FL56+FL57= in­fi­nite pos­si­bil­i­ties? Flag­ship's hy­brid start­up takes ma­chine learn­ing in drug dis­cov­ery to the next lev­el — and Covid-19 of­fers a quick test

Last week
Startups
AI

With pos­i­tive PhI­II da­ta, Mer­ck sets up a block­buster at­tempt to over­throw Pfiz­er's reign­ing Pre­vnar 13

Last week
R&D

Covid-19 roundup: Fau­ci re­it­er­ates Oc­to­ber vac­cine OK 'un­like­ly'; Pfiz­er and BioN­Tech re­serve 200M dos­es for EU

Last week
Coronavirus

Phar­ma's bat­tered rep gets a mod­est facelift in the lat­est in­dus­try rat­ings from Gallup — but it's still look­ing pret­ty bad

Last week
Bioregnum
Pharma

Mer­ck beat Bel­lus, but their full cough da­ta aren't earn­ing much en­thu­si­asm

Last week
R&D

Af­ter care­ful­ly build­ing up ex­pec­ta­tions, a small-cap biotech’s big plans come crash­ing down in PhI­II cat­a­stro­phe

Last week
R&D

Roche nabs an FDA OK for Gavre­to, trig­ger­ing a heavy­weight bout with ri­vals at Eli Lil­ly

Last week
R&D
Pharma

CEOs join reg­u­la­tors and top sci­en­tists vow­ing to hold the line on Covid-19 vac­cine. But will that get in the way of Trump's 'big sur­prise'?

Last week
Bioregnum
Coronavirus

Scott Ed­mond­son leaves As­traZeneca, starts new chap­ter at Nim­bus; With IPO filed, Taysha pulls to­geth­er an AveX­is-heavy team

2 weeks ago
Peer Review

Ab­b­Vie jumps in­to CD47 game, en­gi­neers $3B deal with am­bi­tious Chi­nese play­er

2 weeks ago
Deals
China

Mon­cef Slaoui calls late Oc­to­ber vac­cine roll­out 'ex­treme­ly un­like­ly,' vows again to re­sign un­der un­due po­lit­i­cal in­flu­ence

2 weeks ago
Coronavirus

BIO and a string of CEOs is­sue a call for FDA in­de­pen­dence and against sci­ence-by-press-re­lease

3 weeks ago
Pharma
Regulatory

Ake­bia shares MACEd as their PhI­II ane­mia drug fails on safe­ty, of­fer­ing ri­val Fi­bro­Gen a huge ad­van­tage

3 weeks ago
R&D

Com­ing up be­hind the mR­NA lead­ers, Sanofi, GSK piv­ot in­to PhI/II tri­al for their tra­di­tion­al tech ap­proach to a Covid-19 vac­cine. This race is­n't over yet

3 weeks ago
R&D
Coronavirus

Amy­lyx spot­lights a PhII suc­cess in slow­ing ALS pro­gres­sion. And they’re tak­ing it to the FDA

3 weeks ago
R&D

En­thused by PhII au­toim­mune da­ta, J&J kept Mo­men­ta wait­ing in the lead-up to $6.5B buy­out

3 weeks ago
Deals

Covid-19 roundup: KHN: Fau­ci says Covid vac­cine tri­als could end ear­ly, if...; HHS plans $250M cam­paign to 'de­feat de­spair and in­spire hope'

3 weeks ago
Coronavirus

An­oth­er Big Phar­ma 'lif­er' in the top ranks of R&D is start­ing a new chap­ter in biotech

3 weeks ago
People
R&D

Spurned by the FDA, In­ter­cept brings out the bud­get axe and chops 170 jobs

3 weeks ago
Pharma

That 'his­toric break­through' hyped by Trump and Hahn? The NIH is­n't im­pressed

3 weeks ago
Coronavirus

Wheel­ing and deal­ing his way to a can­cer drug pipeline, Gilead’s Dan O’Day crafts a rich, $805M deal to bag a pre­clin­i­cal I/O drug

3 weeks ago
Deals
R&D
First page Previous page 12345 Next page Last page